Logan S. Spiegelman

Logan S. Spiegelman

Auto-generated profile, based on publicly available information

Logan S. Spiegelman

Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in Cancer Research
Verified
Journal Article
Closed access
TSTriparna Sen
Triparna Sen
EGElisa Gobbini
Elisa Gobbini
KMKhalis Mustafayev
Khalis Mustafayev
LSLogan S. Spiegelman
Logan S. Spiegelman
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.

15 September 2026
Verified
Other
Open access
TSTriparna Sen
Triparna Sen
EGElisa Gobbini
Elisa Gobbini
KMKhalis Mustafayev
Khalis Mustafayev
LSLogan S. Spiegelman
Logan S. Spiegelman
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Incidence of brain metastases at diagnosis and prognosis according to lung cancer histology.

15 September 2026
Verified
Other
Open access
TSTriparna Sen
Triparna Sen
EGElisa Gobbini
Elisa Gobbini
KMKhalis Mustafayev
Khalis Mustafayev
LSLogan S. Spiegelman
Logan S. Spiegelman
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Small cell lung cancer (SCLC) is an aggressive malignancy marked by rapid progression, early dissemination, and a pronounced propensity for brain metastases (BM), which develop in up to 80% of patients. SCLC is defined by profound genomic instability, lineage plasticity, and rapid drug resistance. The establishment of BM is promoted by neuronal mimicry, enhanced intercellular adhesion, and dynamic cross-talk with astrocytes and microglia. Emerging therapies targeting delta-like ligand 3 and B7H3 have demonstrated encouraging intracranial activity. Despite these advances, treatment resistance and limited brain drug penetration remain major unmet needs. This review highlights recent advances in SCLC BM biology and precision therapeutic strategies.